

Supplementary Online Content

Keim SA, Boone KM, Klebanoff MA, et al. Effect of docosahexaenoic acid supplementation vs placebo on developmental outcomes of toddlers born preterm: a randomized clinical trial. *JAMA Pediatr*. Published online October 22, 2018. doi:10.1001/jamapediatrics.2018.3082

eTable. Change from Baseline to Trial Completion in Developmental Outcomes, Subgroup Results, Omega Tots Trial (n=377), 2012-2017

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Change from Baseline to Trial Completion in Developmental Outcomes, Subgroup Results, Omega Tots Trial (n=377), 2012-2017

Outcomes	DHA+AA/p lacebo, No. at baseline	Baseline score mean (SD)		DHA+AA/p lacebo, No. at end of trial	Score at end of trial mean (SD)		Mean change (SD)		Difference in Change ^b	95% CI for Difference	ANCOVA effect size	p- value
Cognitive composite												
Income ≤\$35,000	84/89	94.9 (15.2)	101.1 (11.6)	68/78	95.1 (13.1)	96.5 (10.4)	-0.4 (12.9)	-4.7 (13.4)	0.9	-2.6, 4.4	0.09	0.60
>\$35,000	103/95	103.5 (11.5)	101.3 (11.0)	101/87	99.6 (10.5)	98.7 (11.9)	-4.1 (13.5)	-2.7 (11.2)	-0.2	-3.3, 2.9	-0.01	0.89
Child sex – female	83/98	99.6 (15.0)	100.9 (12.3)	74/89	99.0 (12.7)	97.3 (10.7)	-1.6 (13.6)	-3.4 (12.3)	1.6	-1.6, 4.9	0.18	0.32
Male	105/90	99.8 (13.1)	101.8 (10.5)	95/80	96.8 (11.0)	98.2 (12.4)	-3.4 (13.2)	-4.0 (12.1)	0.0	-3.2, 3.2	-0.05	0.99
Birthweight <1250g	44/36	93.8 (16.3)	98.1 (13.6)	40/34	93.0 (12.8)	94.1 (10.5)	-2.4 (13.8)	-4.0 (14.0)	-0.1	-5.0, 4.9	-0.01	0.97
≥1250g	143/152	101.5 (12.7)	102.1 (10.7)	128/135	99.4 (11.0)	98.6 (11.6)	-2.6 (13.3)	-3.7 (11.7)	0.9	-1.7, 3.4	0.08	0.51
Language composite												
Income ≤\$35,000	84/89	90.2 (12.9)	92.5 (10.8)	68/78	90.3 (13.7)	90.8 (11.8)	-0.4 (13.4)	-1.1 (12.3)	0.1	-3.6, 3.8	0.01	0.95
>\$35,000	102/95	94.3 (11.3)	94.0 (13.1)	101/87	94.0 (11.0)	95.5 (13.5)	-0.6 (11.1)	1.5 (12.8)	-2.0	-5.0, 1.1	-0.17	0.21
Child sex – female	82/98	93.5 (13.0)	93.9 (13.3)	74/89	94.8 (13.9)	94.2 (13.9)	0.9 (12.2)	0.5 (13.9)	0.2	-3.4, 3.9	0.04	0.90
Male	105/90	91.7 (11.4)	92.4 (10.5)	95/80	90.8 (10.7)	92.1 (12.9)	-1.6 (11.8)	-0.1 (11.0)	-1.2	-4.3, 1.9	-0.14	0.45
Birthweight <1250g ^c	43/36	89.3 (14.7)	92.6 (13.7)	40/34	88.5 (14.0)	94.1 (12.4)	-2.2 (14.3)	1.1 (13.4)	-4.4	-9.9, 1.1	-0.39	0.12
≥1250g	143/152	93.6 (11.2)	93.3 (11.7)	128/135	93.8 (11.5)	93.0 (13.4)	-0.0 (11.3)	0.0 (12.5)	0.3	-2.3, 2.9	0.03	0.82
Motor composite												
Income ≤\$35,000 ^d	84/89	92.6 (14.5)	96.0 (10.8)	68/78	94.1 (13.5)	97.1 (10.4)	0.4 (11.2)	1.2 (10.8)	-1.7	-4.9, 1.5	-0.19	0.29
>\$35,000	102/95	98.9 (12.6)	96.5 (11.5)	100/87	97.8 (8.4)	94.9 (14.2)	-1.2 (13.4)	-1.8 (14.4)	2.0	-1.2, 5.3	0.21	0.21
Child sex – female	82/98	97.2 (13.9)	95.6 (11.4)	73/89	97.3 (10.6)	96.6 (11.2)	-0.9 (12.4)	0.7 (11.1)	-0.4	-3.3, 2.6	-0.02	0.81
Male	105/90	95.2 (13.7)	97.0 (10.8)	95/80	95.5 (11.0)	95.2 (13.9)	-0.3 (12.7)	-1.6 (14.2)	1.4	-1.9, 4.8	0.06	0.40
Birthweight <1250g	43/36	90.2 (17.3)	92.5 (12.7)	40/34	92.8 (14.4)	95.1 (11.4)	0.8 (13.1)	2.5 (7.9)	-0.9	-5.1, 3.3	-0.20	0.66
≥1250g	143/152	97.8 (12.1)	97.2 (10.6)	127/135	97.4 (9.3)	96.2 (12.8)	-1.0 (12.4)	-1.1 (13.6)	0.8	-1.8, 3.4	0.08	0.54
Effortful control												
Income ≤\$35,000 ^e	85/88	5.2 (0.7)	5.4 (0.8)	64/75	4.5 (0.8)	4.6 (0.8)	-0.7 (0.9)	-0.7 (0.8)	0.0	-0.3, 0.2	-0.03	0.85
>\$35,000	103/95	5.3 (0.7)	5.1 (0.8)	96/84	4.6 (0.7)	4.7 (0.8)	-0.7 (0.7)	-0.3 (0.7)	-0.3	-0.4, -0.1	-0.37	0.01
Child sex – female	83/97	5.4 (0.7)	5.4 (0.8)	70/87	4.8 (0.8)	4.8 (0.8)	-0.6 (0.8)	-0.6 (0.8)	-0.1	-0.3, 0.2	-0.05	0.57
Male	105/88	5.1 (0.7)	5.0 (0.7)	90/76	4.4 (0.7)	4.5 (0.8)	-0.7 (0.8)	-0.5 (0.8)	-0.1	-0.4, 0.1	-0.21	0.20
Birthweight <1250g	45/36	5.2 (0.8)	5.3 (0.8)	39/32	4.5 (0.9)	4.6 (0.9)	-0.6 (0.8)	-0.7 (0.9)	-0.1	-0.4, 0.3	-0.04	0.72
≥1250g	142/149	5.3 (0.7)	5.2 (0.8)	120/131	4.6 (0.7)	4.7 (0.8)	-0.7 (0.8)	-0.5 (0.8)	-0.1	-0.3, 0.1	-0.18	0.17

Outcomes	DHA+AA/p lacebo, No. at baseline	Baseline score mean (SD)		DHA+AA/p lacebo, No. at end of trial	Score at end of trial mean (SD)		Mean change (SD)		Difference in Change ^b	95% CI for Difference	ANCOVA effect size	p- value
Activity level												
Income ≤\$35,000	85/89	4.9 (1.3)	4.9 (1.3)	63/75	5.4 (1.2)	5.6 (1.2)	0.6 (1.8)	0.8 (1.6)	-0.1	-0.5, 0.4	-0.12	0.80
>\$35,000	103/95	4.7 (1.2)	4.9 (1.0)	96/84	5.3 (1.0)	5.2 (1.0)	0.6 (1.3)	0.3 (1.4)	0.1	-0.2, 0.5	0.13	0.37
Child sex – female ^f	83/97	4.7 (1.3)	4.8 (1.2)	70/87	5.5 (1.0)	5.3 (1.1)	0.8 (1.3)	0.6 (1.5)	0.3	-0.1, 0.6	0.21	0.16
Male	105/89	4.9 (1.2)	5.0 (1.1)	89/76	5.3 (1.2)	5.5 (1.1)	0.4 (1.6)	0.5 (1.5)	-0.2	-0.6, 0.2	-0.18	0.26
Birthweight - <1250g	45/36	4.9 (1.2)	4.9 (1.1)	38/32	5.3 (1.2)	5.3 (1.0)	0.6 (1.5)	0.4 (1.5)	0.1	-0.5, 0.7	0.06	0.72
≥1250g	142/150	4.8 (1.2)	4.9 (1.2)	120/131	5.4 (1.1)	5.4 (1.2)	0.6 (1.5)	0.5 (1.5)	0.0	-0.3, 0.3	0.01	0.90

^a One child's baseline Bayley-III assessment was deemed invalid.

^b Difference in change column is based on mixed effects model (analogous to ANCOVA) using maximum likelihood to account for missing data (39 children did not participate in the last trial visit) and thus may differ from the results of the raw summary statistics presented for the within-group mean change and standard deviation (SD). Positive numbers indicate the effect tended to favor DHA even if not statistically significant.

^c Interaction $P=0.12$.

^d Interaction $P=0.10$.

^e Interaction $P=0.17$.

^f Interaction $P=0.07$.

Missing data: income for 5 participants, birthweight for 1 participant.